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The lysosomal storage disorder Fabry disease is characterized by a deficiency of the
lysosomal enzyme α-Galactosidase A. The observation that missense variants in the
encoding GLA gene often lead to structural destabilization, endoplasmic reticulum reten-
tion and proteasomal degradation of the misfolded, but otherwise catalytically functional
enzyme has resulted in the exploration of alternative therapeutic approaches. In this
context, we have investigated proteostasis regulators (PRs) for their potential to increase
cellular enzyme activity, and to reduce the disease-specific accumulation of the bio-
marker globotriaosylsphingosine in patient-derived cell culture. The PRs also acted syner-
gistically with the clinically approved 1-deoxygalactonojirimycine, demonstrating the
potential of combination treatment in a therapeutic application. Extensive characterization
of the effective PRs revealed inhibition of the proteasome and elevation of GLA gene
expression as paramount effects. Further analysis of transcriptional patterns of the PRs
exposed a variety of genes involved in proteostasis as potential modulators. We propose
that addressing proteostasis is an effective approach to discover new therapeutic targets
for diseases involving folding and trafficking-deficient protein mutants.
Introduction
Fabry disease (FD, OMIM 301500) is one of more than 40 lysosomal storage diseases (LSD) [1].
According to recent data, FD is possibly the most common LSD with an incidence found to be 1 : 1
250 to 1 : 37 800 [2] depending on the severity of symptoms. FD is caused by mutations in the
X-linked gene encoding the lysosomal enzyme α-Galactosidase A (gene symbol: GLA, protein: α-Gal
A) leading to absent or diminished activity of the enzyme [3]. Many missense variants of the GLA
gene lead to impaired protein processing within the endoplasmic reticulum (ER) and an altered con-
formation that results in ER retention and premature ER-associated degradation (ERAD) [4].
Deficient activity of α-Gal A, in turn, causes progressive accumulation of Globotriaosylceramide (Gb3)
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or its metabolite Globotriaosylsphingosine (lyso-Gb3) [3]. The measurement of lyso-Gb3 in plasma and whole
blood is considered of diagnostic as well as of prognostic value for the assessment of the clinical outcome of
GLA mutations [5–7].
The current therapeutic strategy involves enzyme replacement therapy (ERT) with intravenous infusions of
α-Gal A. Different formulations are available from different sources and manufacturers. The benefit of ERT
may be impaired by many limitations including an insufficient penetration in key tissues [8], an immune
response leading to the formation of IgG antibodies that may hamper the effectiveness of the treatment [9], the
patient burden of a life-long inconvenient intravenous therapy and high cost. The clinical approval of the orally
available pharmacological chaperone (PC) therapy using the active-site specific sugar mimetic 1-
deoxygalactonojirimycine (DGJ) represents a recent therapeutic advance for a fraction of FD patients [10].
These patients harbor missense variants, which are associated with a destabilized though catalytically active
α-Gal A enzyme. The effectiveness of DGJ is based on its direct binding to the immature α-Gal A within the
ER. The variant enzyme then attains a thermodynamically favored folding state, which leads to a reduced elim-
ination by ERAD and, consequently, to a shift to a greater enzyme fraction being further transported along the
secretory route to the lysosomes raising the level of available, active α-Gal A [11].
New therapeutic approaches include the use of small molecules, which have the capacity to modify proteosta-
sis, including protein synthesis, folding and degradation. They either increase the folding capacity of the ER or
enhance the degradation of misfolded proteins in order to resolve the protein overload [12]. Therefore, they are
referred to as proteostasis regulators (PRs). Many of these have been proposed as potential candidate drugs in
protein misfolding and aggregation diseases (e.g. Cystic Fibrosis, Alzheimer’s disease, retinitis pigmentosa) [12–
15] and particularly LSD [16–20]. Either the protein variants that have resulted in the diseases are to be
removed from the system, since toxic gain-of-function variants have developed, or the functionality of the
protein must be restored by preventing degradation, i.e. a rescue of loss-of-function. Depending on the goal to
be pursued, the properties of an effective drug are determined. Proteostasis is maintained by a highly conserved
cellular machinery that regulates protein folding in general, and specifically, the protein misfolding-induced
unfolded protein response (UPR) which activates the ERAD [21–23]. Signal integration within the proteostasis
network is associated with extensive gene regulation [24,25] and leads to cell type-specific transcriptional pat-
terns in response to stress in order to restore homeostasis [26]. The relation between protein folding diseases
and the expression of proteostasis genes is being examined by a growing research community [16,17,21,23,27–
33]. Additionally, the role of gene expression regulation, particularly of genes involved in proteostasis processes,
has been proposed to be part of the work mechanism of PRs besides their primary biochemical function
[16,17,21,27–30,33]. This gene regulator function of PRs might have an impact on the rescue of misfolded pro-
teins. First indications for a meaningful use of PRs in FD can be found in earlier studies [34,35].
The aim of this study was to screen for candidates able to increase variant α-Gal A activity in patient-derived
fibroblasts harboring the PC amenable variants c.902G>A (p.R301Q) and c.901C>G (p.R301G), respectively,
and to provide a profound characterization of the effects on the proteostasis network.
Materials and methods
Chemicals
Chemicals were purchased from Sigma–Aldrich (Steinheim, Germany) except for 17-AAG (Abcam,
Cambridge, U.K.); Rosiglitazon, Clasto-Lactacystin β-lactone (CLC), Eeyarestatin I (EerI) and Ritonavir
(Cayman Chemicals, Ann Arbor, MI, U.S.A.); Pifithrin-μ (Enzo Life Sciences, Lörrach, Germany); Lacidipine
(Key Organics, Cornwall, U.K.); MG132 (Merck (Darmstadt, Germany); 15d-PGJ2 (Santa Cruz Biotechnology,
Dallas, TX, U.S.A.); Kifunensine and 1-deoxygalactonojirimycine hydrochloride (Toronto Research Chemicals,
Toronto, Canada) and Bortezomib (USBiological, Salem, MA, U.S.A.).
Cell culture
Wild-type (WT) fibroblast cell lines GM01653 (wild-type 1, WT1), GM23249 (WT2), GM23250 (WT3),
GM23968 (WT4) from healthy male donors and Fabry fibroblasts hemizygous for the c.901C>G (p.R301G)
variant (GM00882, GLAp.R301G/°) were purchased from Coriell Institute cell repository (Camden, U.S.A.). Male
Fabry fibroblasts hemizygous for the c.902G>A (p.R301Q) variant (GLAp.R301Q/°) were a kind gift of Amicus
Therapeutics (Cranbury, NJ, U.S.A.). Both variants were reported to be amenable to PC treatment [5,35]. All
lines were sequenced prior to use to verify the genotypes. Fabry disease was excluded for all healthy donors.
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However, GM23249 carried the intronic haplotype found to be associated with reduced mRNA expression [36].
Fibroblasts were cultured in Dulbecco’s modified Eagle medium containing 4.5 g glucose/l (Gibco, Carlsbad,
CA, U.S.A.) supplemented with 15% heat-inactivated fetal bovine serum (Gibco) and 1% Penicillin/
Streptomycin (Invitrogen, Carlsbad, CA, U.S.A.) at 37°C in 5% CO2. Monolayers were passaged with 0.25%
Trypsin-EDTA (Fisher Scientific, Schwerte, Germany) when reaching full confluency.
Drug treatment
The patients’ fibroblasts were seeded one day prior to the treatment to give the cells time to adhere to the
surface of the culture vessel. At the beginning of the treatment, the cells typically had ∼80% confluency. The
cells were treated with PR, DGJ, and a combination of both. The exact duration of the treatment and the drug
concentrations used can be seen in the figures. Typically, the treatment was followed by a 6-h off-treatment
period (‘washout’) for enzyme activity measurement, because α-Gal A required this recovery phase for stable
assessment after DGJ treatment (Supplementary Figure S1) and a 4 days washout for biomarker measurements
as reported before [37]. The PR treatment was also discontinued for the washout period. After the treatment,
the cells were processed according to the downstream application as described in the following paragraphs.
α-Galactosidase A activity assay
After the treatment for the indicated time, the activity assay was run. The cells were harvested with 0.25%
Trypsin-EDTA, washed with phosphate-buffered saline (PBS), resuspended in deionized water and lysed during
five freezing and thawing cycles. The protein amount in the cell lysates was determined using the BCA protein
assay kit (Thermo Scientific, Waltham, MA, U.S.A.). Five micrograms of total protein was used for enzyme
activity measurement with the substrate analog 4-methylumbelliferyl-α-D-galactopyranoside. The reaction
product 4-methylumbelliferone was recorded at 360 nm excitation and 460 nm emission in a fluorescence plate
reader as described earlier [38].
Lyso-Gb3 determination in patient-derived fibroblasts
We seeded 2 × 105 fibroblast cells and treated them with PRs for the specified period of time. On the day of
harvest, the cells were trypsinized then pelleted, washed with PBS, resuspended in 70 ml deionized water and
vortexed for 3 min. The cell suspension was lysed during six cycles of freezing in liquid nitrogen and sonication
for 5 min. Samples were centrifuged and the supernatant with the protein extract was transferred to a new
tube. The protein amount in the cell lysates was determined using the BCA protein assay kit (Thermo
Scientific). Sample preparation for lyso-Gb3 determination and the mass spectrometric analysis was performed
as described [39]. For each batch of analyses, a calibration curve was added with a concentration range from 0
to 1 000 ng/ml in water. The concentration of the lyso-Gb3 was recorded in ng/mg protein extract.
Lipid extraction
Lipids were extracted according to Bligh and Dyer [40] with slight modifications. 1 × 106 human fibroblasts
were seeded and cultured for the indicated time points with and without treatment. On the day of cell harvest,
the cells were pelleted in non-adhesive wall glass tubes (Schott AG, Mainz, Germany) allowing for lipid extrac-
tion. A mixture of chloroform, methanol and hydrochloric acid (2 :4 : 0.1) was added to the samples together
with 1% butylated hydroxytoluol, to prevent lipid oxidation. In addition, a fluorescent internal standard,
TopFluor® Lyso PA was added at a concentration of 1 mg/ml to ensure the reproducibility of the lipid extrac-
tion. The compound is a synthetic lipid, and therefore absent from the real samples. The fluorescence was later
measured by CAMAG visionCATS at 366 nm. Chloroform was added to the homogenized samples and vor-
texed three times with a 10 min break in between. Next, water was added to the samples and vortexed three
times with a 10 min break in between, followed by 30 min incubation and centrifugation at 1260 ×g for 10
min. A biphasic separation was visible, and the bottom phase containing a mix of chloroform and lipids was
transferred into a new non-adhesive wall glass vessel. Finally, the chloroform was evaporated in an N2
chamber, fresh chloroform was added, and the bottles were stored at −20°C until use.
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Separation and analysis of Gb3 by high-performance thin-layer
chromatography (HPTLC) and Far-Eastern blot
Samples were transferred to the HPTLC with an automatic TLC Sampler 4 (ATS 4) from CAMAG. The sta-
tionary phase was 10 × 10 cm silica gel (60 F254 Merck, KGaA, Darmstadt, Germany). For the mobile phase a
chloroform (SupraSolv Merck KGaA, Darmstadt, Germany), methanol (LiChroSolv Merck KGaA, Darmstadt,
Germany), ammonia 32% (HiPerSolv VWR Chemicals, Radnor, PA, U.S.A.), water (Rotisolv Carl Roth GmbH,
Karlsruhe, Germany) solution at a ratio of 161 : 75 :5 : 10 was used. Lipids then developed on the HPTLC plate
were sprayed with primuline reagent (Derivatizer, CAMAG) and visualized under ultraviolet light (366 nm,
TLC Visualizer, CAMAG).
Far-Eastern blotting was made according to Taki et al. [41], with slight modifications (TLC blot (far-eastern
blot)) and its applications. The plate was immersed in a mixture of isopropanol 0.2% CaCl2 : methanol (40 :
20 : 7, v/v/v) for 2 s, then covered with an activated polyvinylidene difluoride (PVDF) membrane (0.45 mm GE
Healthcare Amersham Hybond, Fisher Scientific, Pittsburgh, PA, U.S.A.) and a glass microfiber filter (APFF,
Merck, KGaA, Darmstadt, Germany). The transfer cassette was pressed for 30 s with an iron heated at 180°C,
after which the PVDF membrane was separated from the plate and dried.
PVDF membrane was blocked over night at 4°C with 0.1% BSA diluted in PBS followed by antibody incuba-
tion with anti-Gb3 (1 : 1000, TCI, amsbio, Mainz, Germany) in 3% BSA/PBS for 2 h at RT. The secondary anti-
body used was Mouse Ig, HRP-Linked Whole Ab, Sheep (1 : 5000, ECL) conjugated to horseradish peroxidase.
After incubation for 1 h at RT, Gb3 was detected using clarity western ECL Substrate (Bio-Rad 1705061 1 : 1)
and analyzed by using ImageLab 6.0 software (Bio-Rad Laboratories, Hercules, CA, U.S.A.).
Synergy analysis
All calculations were performed using R 3.3.0. The synergyfinder [42] tool was used in version 1.3.0 (with
minor patches, see https://github.com/struckma/synergyfinder). For calculating the three-dimensional inter-
action surface over the dose matrix, the package synergyfinder was used as well. For synergy analysis, the
enzyme activity after the treatment of GLAp.R301Q/° was calculated as the percentage of the maximal determined
activity. The enzyme activity of the untreated control cells was subtracted from the non-control samples.
Synergy values (excess over bliss, eob) were determined by calculating the difference between the actual enzyme
activity after the combined treatment and the expected additive drug effect given by the BLISS independence
model [43] and calculated with the following equation: ED + EB – ED * EB. Here, ED represents the enzyme activ-
ity after single treatment with DGJ and EB describes the effect of the respective Bortezomib (BTZ) concentra-
tion. Synergy was called if the achieved enzyme activity after the combined treatment was higher than the
expected additive effect. The BLISS synergy scores for each treatment were plotted as a function of the two
drug concentrations.
Western blot analysis
Cultured WT and GLAp.R301Q/° fibroblasts were pelleted, washed with PBS and resuspended in 45 ml RIPA
buffer containing complete protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany) followed by a
20 min incubation on ice to complete the lysis. After centrifugation of the samples, the supernatants were used
for protein measurement using the BCA protein assay kit (Thermo Scientific) according to the specifications by
the manufacturer. The PNGase digestion was carried out using the PNGase F kit from New England Biolabs
(Ipswich, MA, U.S.A.) according to the manufacturer’s specifications. Hundred micrograms of protein per
sample were mixed with Laemmli buffer and incubated for 5 min at 95°C. For the separation of the proteins,
SDS–PAGE was performed using the precast 4–15% Criterion™ TGX Stain-Free™ Protein Gels (Bio-Rad
Laboratories). Proteins were transferred to a nitrocellulose membrane (GE Healthcare, Braunschweig,
Germany), using the Trans-Blot® Turbo™ Midi Nitrocellulose Transfer Packs and the Trans-Blot® Turbo™
Transfer System (Bio-Rad Laboratories). The membrane was blocked in 5% non-fat dried skim milk solution
for 1 h at room temperature and incubated with primary rabbit polyclonal GAPDH antibody (Abcam,
Cambridge, U.K.) at a 1 : 10 000 dilution in TBS-Tween 20 supplemented with 3% non-fat dried skim milk at
4°C overnight. Afterwards, the membrane was washed five times with TBS-Tween 20, incubated with mouse
monoclonal α-Gal A antibody at a 1 : 500 dilution in TBS-Tween 20 supplemented with 3% non-fat dried skim
milk (Abcam, Cambridge, U.K.) for 2 h at room temperature and washed again with TBS-Tween 20. Then, the
membrane was treated with 1 : 20 000 diluted secondary goat anti-rabbit antibody (LI-COR Biosciences,
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Lincoln, NE, U.S.A.) and 1 : 10 000 diluted goat anti-mouse antibody (Rockland Immunochemicals, Limerick,
PA, U.S.A.), both diluted in TBS-Tween 20 including 3% non-fat dried skim milk, for 2 h at room temperature
protected from light. After a final washing step, the blots were visualized using an Odyssey® Infrared Imager
(LI-COR Biosciences). The determination of the protein size and the quantification of the bands were done
using the Odyssey Application Software version 1.2.
Proteasomal activity assay
Specific proteasome inhibition was examined using the Cell-Based Proteasome-Glo™ Assays (Promega,
Madison, WI, U.S.A.) according to the manufacturer’s protocol. One day before the assay GLAp.R301Q/° fibro-
blasts were seeded in 24-well plates (Sarstedt, Nümbrecht, Germany) and cultured overnight. The experiment
was initiated by the addition of the compound. The cells were incubated for 2 h. For the luminometric meas-
urement, the cells were harvested by scraping and 20 000 cells were dissolved in 100 ml PBS + compound. An
equal volume of Proteasome Proteasome™-Glo Reagent (Promega) specific for chymotrypsin-like activity
determination was added [44] and the suspension was incubated for 10 min followed by a measurement with a
Lumat 9507 instrument (Berthold Technologies, Bad Wildbad, Germany) with a measurement time of 2 s.
Quantitative real-time PCR
GLAp.R301Q/° fibroblasts were treated for 24 h. The cells were harvested and 2 ml of the crude RNA extract was
reverse transcribed using the FastLane Cell cDNA kit (Qiagen, Hilden, Germany) according to the
manufactureŕs specification. PCR samples were prepared with the FastStart Essential DNA Green Master kit
(Roche, Mannheim, Germany) according to the manufacturer’s specification. Primer sequences were
50-TTCAAAAGCCCAATTATACAGAAA-30 (forward) and 50-CTGGTCCAGCAACATCAACA-30 (reverse) for
GLA and 50-TGCCCCCGACCGTCTAC-30 (forward) and 50-ATGCGGTTCCAGCCTATCTG-30 (reverse) for
G6PD, respectively. PCR was carried out with the LightCycler® Nano (Roche, Mannheim, Germany) in combin-
ation with the LightCycler® Nano SW 1.1 software. Changes of mRNA amounts were calculated using the effi-
ciency corrected relative quantification model [45].
Microarray analysis
1.2 × 106 GLAp.R301Q/° fibroblasts were seeded in 10 cm dishes and treated with the indicated compound for
24 h (see Supplementary Table S1). Each condition was performed in quadruplicate. The cells were homoge-
nized in Buffer RLT Plus of the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). Total RNA was purified
utilizing the RNeasy Plus Mini Kit according to the manufacturer’s specification. Microarray-based gene expres-
sion analysis was performed with GeneChip® Human Transcriptome Arrays 2.0 (Affymetrix, St. Clara, CA, U.S.
A.). The RNA samples were amplified and labeled using the GeneChip® WT PLUS Reagent Kit (Thermo
Fisher Scientific) according to the manufacturer’s instructions. For the overnight hybridization, the GeneChip®
Hybridization Oven (Affymetrix) was utilized and the visualization was done using the GeneChip Scanner
3000/7G (Affymetrix). The original data were subjected to quality control using the Expression Console
Software (Version 1.4.1.46, Affymetrix). Background correction and normalization were performed using the
Robust Multichip Average procedure [46]. Differentially expressed genes were identified by moderated t-test
with Benjamini–Hochberg P-value adjustment. An absolute fold change≥ 1.5 coupled with an adjusted
P-value ≤ 0.05 were considered significant.
Wikipathways analysis
Transcriptional signatures of MG132, BTZ, CLC and EerI were analyzed for pathway annotation.
WikiPathways analysis was performed using the R software version 3.2.3 utilizing the Bioconductor package
org.Hs.eg.db [47].
Extended proteostasis gene signature
We compiled an extended ERAD/proteasome gene signature. We obtained a list of known ERAD/proteostasis
genes [23]. We then constructed a gene-centric interaction network based on the STRING 10.0 interactome
database. Querying this network with the candidate genes yielded multiple network subcomponents. We identi-
fied genes that could parsimoniously bridge these subcomponents, yielding a set of additional ERAD/proteosta-
sis candidate genes. We subjected these candidate genes to a manual review to positively establish their
involvement in ERAD/proteostasis, assessing whether they were annotated with GO terms related to ER
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 363
Biochemical Journal (2020) 477 359–380
https://doi.org/10.1042/BCJ20190513
D
ow
nloaded from
 https://portlandpress.com
/biochem
j/article-pdf/477/2/359/866702/bcj-2019-0513.pdf by guest on 19 June 2020
protein folding, UPR or ERAD. Finally, the candidate gene list was augmented by adding ubiquitin associated
E1/E2 and proteasome-associated genes utilizing the respective HGNC gene lists. Three hundred and fifty-seven
genes were identified that are in the described context with proteostasis.
Statistical analysis
Statistical data analysis was carried out using GraphPad Prism 5 (GraphPad Software Inc., U.S.A.), Excel soft-
ware (Microsoft, U.S.A.) and R software (R Foundation). Experimental data are given as mean ± SD.
Differences between treatment groups were analyzed using One-way ANOVA with post-hoc Dunnett test as
indicated (*, **, ***, ****P-values of 0.05, 0.01, 0.001 and <0.0001). The number of independent experiments is
indicated in the figure legends.
Results
Abnormal changes in Fabry patient-derived fibroblasts
Enzymatic α-Gal A activity in patient-derived fibroblasts from adult male hemizygous Fabry patients harboring
the variants p.R301Q (GLAp.R301Q/°) and p.R301G (GLAp.R301G/°) was initially compared with four fibroblast
cell lines from healthy age and sex-matched donors (WT 1–4) (Figure 1A). The values for the enzyme activity
in GLAp.R301Q/° (16.70 ± 3.70 nmol 4-MU/mg protein/h) and GLAp.R301G/° (12.28 (±4.93) nmol 4-MU/mg
protein/h) fibroblasts, respectively, were reduced compared with the WT cells (58.5 (±31.1) nmol 4-MU/mg
protein/h). Both common FD storage products lyso-Gb3 and Gb3 were also analyzed. Lyso-Gb3 showed a sig-
nificant increase in both patient cell lines compared with WT1 cells (Figure 1B). The Gb3 level of GLAp.R301Q/°
fibroblasts was also found to be elevated (Supplementary Figure S2).
Proteostasis regulators as effective α-Gal A enhancers
In this study, we first screened 23 PRs as potential variant α-Gal A activity enhancers (Table 1). To this end,
GLAp.R301Q/° fibroblasts were treated with proteostasis regulating substances of varying concentrations for 5
days. For the treatment with DGJ and all DGJ combinations, a 6-h non-treatment phase was applied before
cells were harvested (see Materials and methods). A substance was considered effective if the mean value of
enzyme activity increased by more than 1.2 times compared with untreated GLAp.R301Q/° fibroblasts and statis-
tical significance was obtained from at least three independent measurements. The proteasome inhibitors
MG132, BTZ and CLC were classified as effective activity enhancers of variant p.R301Q. Enzyme activity in
GLAp.R301Q/° cells was elevated up to 2.1-fold by MG132 and BTZ, which is comparable to the 1.9-fold increase
observed with 50 mM DGJ (Figure 2A). CLC increased the activity of α-Gal A up to 1.7-fold. The
concentration-dependent effect of the active PRs is shown in Supplementary Figure S3. When testing the sub-
stances with GLAp.R301G/° fibroblasts, the concentrations most effective in the GLAp.R301Q/° cells showed a high
efficacy, enhancing the variant p.R301G enzyme up to 6.5-fold (MG132), 8.5-fold (BTZ) and 4.1-fold (CLC),
respectively (Figure 2B).
Proteostasis regulators with synergistic effects in combination with DGJ
Both the GLAp.R301Q/° and the GLAp.R301G/° cell lines were treated with a combination of the PRs and 50 mM
DGJ. After 5 days of treatment, α-Gal A activity was significantly increased when compared with the single
treatment with DGJ (Figure 3A,B). Evidently, MG132 and BTZ increased the DGJ effect from 2-fold up to
6.5-fold and 6.8-fold, respectively, in GLAp.R301Q/° cells, and up to 13.2-fold and 17.8-fold, respectively, in
GLAp.R301G/° cells. The combination of DGJ and CLC resulted in a 4-fold and 7-fold increase in enzyme activ-
ity in GLAp.R301Q/° and GLAp.R301G/° fibroblasts, respectively. EerI, which inhibits the Sec61-mediated protein
translocation from the ER into the cytosol, had no significant effect in GLAp.R301Q/° fibroblasts when used as a
single substance (Figure 2A), but in combination with DGJ, a significant effect beyond that of DGJ single treat-
ment was observed up to 3.3-fold of the untreated and 1.9-fold of the DGJ single treated state, respectively
(Figure 3A). In GLAp.R301G/° cells a 4.3-fold increase above untreated and 2.2-fold above DGJ single treatment
was achieved (Figure 3B). Hence, EerI was evaluated as an effective substance. The secretolytic and mucoactive
agent Ambroxol (ABX) was formerly described as a potential PC for FD [35]. ABX at a concentration of
10 mM slightly elevated the effect obtained with DGJ single treatment by 1.1-fold in GLAp.R301Q/° (Figure 3A)
and by 1.3-fold in GLAp.R301G/° fibroblasts (Figure 3B), respectively. Even though this was a bit less than the
effect observed on these two variants in HEK293H cells in the previous study, ABX was included in the further
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analyses. The remaining PRs listed in Table 1 were inactive in both single and combination treatment with
DGJ (data not shown).
Based on the BLISS independence model, the synergistic mechanism of action was determined for the com-
binations of DGJ plus BTZ. The BLISS model provides a formula for the investigation of the interaction of two
simultaneously applied compounds to determine the efficacy of combination treatments. To examine the
dynamics of the most effective combination treatment, different concentration ranges of DGJ (1–200 mM) and
BTZ (1–10 nM) were combined for the treatment of GLAp.R301Q/° fibroblasts (Figure 3C). Exceeding the clinic-
ally achievable plasma concentration by 20 times, DGJ at a concentration of 200 mM triggered an increase in
α-Gal A activity up to 60% of the mean normal activity obtained from four WT fibroblast lines (35.3
(±5.4) nmol 4-MU/mg protein/h). However, only 5 nM BTZ were sufficient to increase the activity of variant
α-Gal A in combination with the clinically effective 10 mM DGJ up to the normal level (84.6 (±6.8) nmol
4-MU/mg protein/h). The maximum effect was achieved with the combination of 200 mM DGJ + 5 nM BTZ.
To get a better overview of the synergy of DGJ and BTZ, an analysis based on the BLISS independence model
was performed. Drug interaction of BTZ and DGJ in the GLAp.R301Q/° fibroblasts featured synergy as demon-
strated by the BLISS synergy scores of the combined treatment (Figure 3D).
Bortezomib corrects the Fabry-related cellular phenotype
The α-Gal A protein undergoes a complicated process involving folding and transport in the cell en route to
the lysosome. Higher enzyme activity should correlate with an improved processing of variant α-Gal A. For a
quantitative assessment of α-Gal A, GLAp.R301Q/° fibroblasts were treated with DGJ and BTZ for 5 days with
subsequent washout for 6 h. The occurrence of several N-glycosylated α-Gal A forms renders its quantification
difficult (Figure 4A). In vitro deglycosylation of the enzyme prior to western blot analysis using PNGase F was
applied to collect all cellular α-Gal A forms in a distinct band for a more comprehensive measurement
(Figure 4B). Quantification of the indicated 39 kDa band revealed a reduced α-Gal A protein level by half in
the GLAp.R301Q/° cell line in relation to WT1 fibroblasts (Figure 4C). α-Gal A level tended to be slightly elevated
after the single treatment with 50 mM DGJ or 5 nM BTZ to 1.3-fold and 1.5-fold, respectively (Figure 4C). In
Figure 1. Determination of the pathophysiology of Fabry patient-derived fibroblasts.
(A) WT and FD fibroblasts were cultured for 5 days. Cell homogenates were used to determine enzyme activity with
4-methylumbelliferyl-α-D-galactopyranoside as a substrate. Shown is the substrate turnover per hour per mg protein as the
mean. The wild-type control bar represents the activity obtained from four different fibroblast cell lines. The data are reported
as mean ± SD. Each individual wild-type cell line was tested at least four times. The FD cell activity was obtained from 16
independent experiments. (B) WT1, GLAp.R301Q/° and GLAp.R301G/° fibroblasts were cultured for 7 days followed by lyso-Gb3
determination, which was normalized to the protein amount in each sample (left y-axis). The data are reported as mean ± SD ng
lyso-Gb3/mg protein (left y-axis) and fold change (right y-axis) from three independent experiments. Statistics: Differences
between the groups were analyzed using One-way ANOVA with post-hoc Dunnett test (*, **, ***, ****P-values of 0.05, 0.01,
0.001 and <0.0001). For (B), the statistical evaluation refers to the left y-axis.
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accordance with the enzyme activity measurement (Figure 3A), the combined treatment with DGJ/BTZ
increased the α-Gal A to supraphysiological levels.
It is not possible to prove with certainty how high a potential gain in protein stability or enzyme activity
must be in order to restore normal cell physiology and, hence, provide a clinical benefit. Therefore, an import-
ant result of the treatment is a functional reduction in pathophysiological lyso-Gb3 levels. GLAp.R301Q/°
Table 1 Panel of proteostasis regulators used in this study
Molecular function Small molecule Disease examined
Proteostasis regulator
reference
Ca2+ channel blocker Lacidipine Gaucher disease Wang et al. Chem Biol.
(2011)
Dantrolene Gaucher disease Wang et al. ACS Chem.
Biol. (2011)
Ong et al. Nat. Chem. Biol.
(2010)
Diltiazem Gaucher disease Ong et al. Nat. Chem, Biol.
(2010)
Coinducer of heat shock
proteins (HSPs)
Arimoclomol NPC1 Kirkegaard et al. Sci.
Transl. Med. (2016)
Inhibitor of cyclooxygenase Ibuprofen Cystic fibrosis Carlile et al. J. Cyst Fibros.
(2015)
ERAD inhibitor 17-AAG (HSP90) Glioblastoma
multiforme
Sauvageot et al. Neuro
Oncol. (2009)
Bortezomib (proteasome) Pompe disease Shimada et al. JIMD Rep.
(2015)
Celastrol (proteasome) Gaucher disease,
Tay-Sachs disease
Mu et al. Cell (2008)
Clasto-Lactacystin
β-lactone (proteasome)
Fabry disease Ishii et al. Biochem. J.
(2007)
Eeyarestatin I (VCP) Gaucher disease Wang et al. J. Biol. Chem.
(2011)
Kifunensine (MAN1B1) Gaucher disease Wang et al. J. Biol. Chem.
(2011)
MG132 (proteasome) Gaucher disease,
Tay-Sachs disease
Mu et al. Cell (2008)
Pifithrin-m (HSP70) Cancer Leu et al. Mol. Cell (2009)
Pyr41 (ubiquitination) Fabry disease Lukas et al. Mol. Ther.
(2015)
Ritonavir (proteasome) Solid malignancies Kraus et al. Mol. Cancer
Ther. (2008)
SAHA (histone
deacetylase)
NPC1,
Gaucher disease
Pipalia et al. Proc. Natl
Acad. Sci. U.S.A. (2011),
Lu et al. Proc. Natl Acad.
Sci. U.S.A. (2011)
TSA (histone deacetylase) NPC1 Pipalia et al. Proc. Natl
Acad. Sci. U.S.A. (2011)
Na+ channel blocker/PC Ambroxol Fabry disease/Pompe
disease,
Gaucher disease
Lukas et al. Mol. Ther.
(2015),
McNeill et al. Brain (2014)
PC DGJ Fabry disease Fan et al. Nat. Med. (1999)
Peroxisome
Proliferator-Act-ivated Receptor
agonist
Rosiglitazone (PPARγ) Fabry disease Lukas et al. Mol. Ther.
(2015)
Pioglitazone (PPARγ) Alzheimer’s disease Papadopoulos et al. PLoS
One (2013)
15d-PGJ2 (PPARγ) Multiple myeloma Sperandio et al. Exp. Mol.
Pathol. (2017)
Bezafibrate (PPARα/δ/γ) Fabry disease Lukas et al. Mol Ther.
(2015)
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fibroblasts were treated with 50 mM DGJ and 5 nM BTZ for 7 and 14 days with a subsequent washout for 4
days. After 7 (+4) days, DGJ (10%) and BTZ (32%) single treatment caused an insignificant reduction in
lyso-Gb3 in the cells (Figure 5A). In contrast, the combination of DGJ and BTZ lowered the cellular lyso-Gb3
significantly by 49%. Increasing treatment time to 14 days did not improve the effect of DGJ but enhanced the
BTZ effect after single treatment (60%) as well as in combination with DGJ (70%) (Figure 5B). However, the
differences between the 7-day and 14-day treatment have not been significant being P = 0.2140 for the single
and P = 0.4081 for the combination treatment (unpaired two-sample t-test). The lyso-Gb3 clearance after the
single and combined treatment with DGJ and BTZ followed relatively slow kinetics. It behaves in an almost
linear way within the monitored time of the experiment. Moreover, the lyso-Gb3 level is far from normal,
being 3.8 times higher than in the control fibroblast cell line after the 14-day treatment. Enzyme activity,
however, approached (in case of DGJ, BTZ single treatment) or even exceeded (in case of combined treatment)
the normal level after 5 days (compare Figures 2A and 3A). Therefore, we wanted to determine how enzyme
activity changes during prolonged exposure to treatment and whether the effect can become exhausted, or
potentially, increase over time. At first, only the duration of treatment was adjusted to 14 days, but the washout
time was left at 6 h specified for DGJ (Figure 5C). As expected, enzyme activity increase after DGJ and BTZ
single treatments remained relatively stable compared with 5 days. A slight trend was observed indicating a
stronger increase using longer incubation periods (DGJ: 1.9-fold (5 days) vs. 2.3-fold (14 days), P = 0.0173;
BTZ: 2.1-fold (5 days) vs. 3.0-fold (14 days), P = 0.0921, unpaired two-sample t-test). The combined treatment
was significantly more effective and achieved a 24-fold increase in the initial activity (DGJ/BTZ: 6.8-fold (5
days) vs. 24.0-fold (14 days), P < 0.0001, unpaired two-sample t-test). We then adjusted the washout period
likewise to 4 days in accordance with the lyso-Gb3 experiments (Figure 5D). The DGJ effect resembled the
level observed for the 5-day treatment and 6-h washout regimen while the beneficial effect of BTZ single treat-
ment on the α-Gal A activity could not be observed after 4 days of washout. The combined treatment of DGJ
and BTZ yielded an elevation identical with the level observed for 5-day treatment and 6-h washout (6.8-fold).
Although the combination treatment after 4 days of washout still resulted in a significant increase in activity
compared with the DGJ single treatment, the reduced activity compared with the 14-day treatment and 6-h
washout (6.8-fold vs. 24.0-fold, P < 0.0001, unpaired two-sample t-test) indicates that a part of the BTZ effect
was eliminated by the discontinuation of treatment.
Altogether, these data suggest that the DGJ effect on α-Gal A will persist for prolonged periods of time when
treatment is discontinued. Although the effect produced by BTZ is temporary and decreased rapidly when cells
Figure 2. Enhancement of mutant α-Gal A activity by proteostasis regulators.
GLAp.R301Q/° (A) and GLAp.R301G/° (B) fibroblasts were treated for 5 days with the pharmacological chaperone DGJ and different
proteostasis regulating drugs (MG132, BTZ, CLC and EerI). Reported enzyme activity was normalized to the activity of
untreated mutant control cells. Data are reported as mean ± SD of at least three independent experiments. One-way ANOVA
with post-hoc Dunnett test was carried out to test statistical significance (*, ***P-values of 0.05 and 0.001); n.s., not significant.
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were no longer exposed to treatment, the BTZ effect could reach very high levels through prolonged treatment
time (Figure 5C). Moreover, the lyso-Gb3 reducing effect of BTZ also appears to be sustainable in the inter-
rupted treatment regime (Figure 5A,B). The GLAp.R301G/° fibroblasts showed a significant reduction in lyso-Gb3
with all applied substances using the 7 (+4)-day washout treatment regimen (Figure 5E) and confirmed the
principle trend in the GLAp.R301Q/° cells.
Proteostasis regulators display different effects on the proteasome
The proteasome is a major effector of the PRs by definition, and MG132, BTZ and CLC are known inhibitors
of the proteasomal activity. The decrease in proteasomal function in GLAp.R301Q/° fibroblasts was observed after
the application of the effective concentrations of MG132, BTZ and CLC, but the level of reduction was obvi-
ously very different being 19.8%, 56.5% and 1.5% of the normal activity, respectively (Figure 6A). A concentra-
tion of 50 nM BTZ could further lower the proteasomal activity but had no additional effect on variant α-Gal
Figure 3. Drug synergy of PRs and the pharmacological chaperone DGJ on Fabry disease mutants.
GLAp.R301Q/° (A) and GLAp.R301G/° (B) fibroblasts, respectively, were treated with combinations of DGJ and various PRs.
Reported enzyme activity was normalized to the activity of untreated mutant control cells. For the statistical evaluation, DGJ
treatment was compared with the untreated condition, the combinations were compared with DGJ single treatment. (C) Drug
interaction landscape for enzyme activity in GLAp.R301Q/° fibroblasts was established for DGJ and BTZ. (D) Drug interaction
landscape for enzyme activity in GLAp.R301Q/° fibroblasts based on the BLISS model revealed BLISS Synergy Score of 34.3 as
the representative mean of all calculated single Synergy Scores. Data in (A) and (B) are representative of mean ± SD of at least
three independent experiments. Data in (C) and (D) are reported as mean of 3 independent experiments. Statistics (A,B):
One-way ANOVA with post-hoc Dunnett test (*, **, ***P-values of 0.05, 0.01 and 0.001).
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A activity (Supplementary Figure S3C). Thus, BTZ was most effective in increasing the activity of α-Gal A at
sub-IC50 concentrations related to proteasomal inhibition [48]. Application of DGJ, EerI and ABX had no
effect on the proteasome. Celastrol (CTR) was included in this analysis as a proteasomal inhibitor that was
unable to increase α-Gal A activity in the GLAp.R301Q/° cells in order to obtain a mechanistic explanation for
this finding. Treatment with CTR resulted in an inhibition of the proteasomal activity down to 75.0%. It is
crucial to investigate whether there is a critical threshold of proteasomal activity necessary for the rescue of
variant α-Gal A or, more generally, whether regulation of the degradation of α-Gal A via the proteasome is a
relevant factor at all.
GLA gene expression elevation in GLAp.R301Q/° cells by proteostasis regulators
PRs have an impact on the transcriptome. An obvious suspicion is that the PRs investigated here up-regulate
the mutated GLA gene itself. Thus, we tested whether the effective PRs could trigger GLA gene expression in
Figure 4. Protein level of α-Gal A in GLAp.R301Q/° fibroblasts after treatment with DGJ and BTZ.
WT1 cells and GLAp.R301Q/° fibroblasts were treated for 5 days with 50 mM DGJ and 5 nM BTZ with subsequent washout for
6 h. (A) Protein level of α-Gal A was reduced in GLAp.R301Q/° fibroblasts in comparison with WT1 cells. Treatment with DGJ and
BTZ increased the protein level of α-Gal A in GLAp.R301Q/° fibroblasts above the WT level. (B) Deglycosylation with PNGase
F prior to western blot resulted in a condensation of all antibody-reactive material in a distinct band at ∼39 kDa. (C)
Quantification of (B). Fluorescence intensity of the α-Gal A bands was normalized to the corresponding GAPDH band and to
untreated GLAp.R301Q/° cells. Data represent three independent experiments and are plotted as mean ± SD. Statistics:
Differences between the groups of treated GLAp.R301Q/° fibroblasts were analyzed using One-way ANOVA with post-hoc
Dunnett test (**P-value of 0.01); n.s., not significant.
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the GLAp.R301Q/° fibroblasts. MG132, BTZ, CLC and EerI induced increases in expression levels of up to
7.9-fold, 8.4-fold, 9.2-fold and 5.4-fold (Figure 6B). The application of DGJ and ABX had no effect on GLA
expression. CTR increased the expression level of GLA up to 2.6-fold which indicates that the ability to elevate
GLA gene expression is an important, but not an exclusive attribute of a PR that acts as an enhancer of α-Gal
A activity, and it appears that a critical limit must be exceeded to trigger a functional enzyme activity boost.
Potential role of transcriptional regulation in α-Gal A activity restoration
Given the global impact of PRs on the transcriptome and the proteostasis interactome, in particular, it is of
great relevance to identify genes whose expression level in the cell is significantly altered by the effective PRs.
Unbiased transcriptional profiling could unveil deeper mechanistic insights into PR function and lead to the
identification of new therapeutic targets. Whole transcriptome microarray analysis was therefore performed on
GLAp.R301Q/° fibroblasts after treatment with DGJ and the effective PRs.
We performed principal component analysis (PCA) on the global gene expression profiles (29 799 probesets)
(Supplementary Figure S4). Broadly, the samples can be grouped into three clusters, which are distinguished by
their PC1 scores, having high inter- and low intra-cluster variance. One of the clusters comprises the untreated
DMSO controls, single treatments of ABX and DGJ and the combination treatment thereof. This indicates that
the global impact of those treatments on the transcriptome is rather limited. On the other hand, a cluster
Figure 5. Lyso-Gb3 level and α-Gal A activity in GLAp.R301Q/° cells in response to prolonged treatment with DGJ and
BTZ.
GLAp.R301Q/° fibroblasts were treated for 7 days (A) or 14 days (B) with 50 mM DGJ, 5 nM BTZ and the DGJ/BTZ combination
with subsequent washout for 4 days. Lyso-Gb3 values were normalized to DMSO-treated GLAp.R301Q/° cells. The white
barshows the lyso-Gb3 level in DMSO-treated WT1 fibroblasts. (C) α-Gal A activity after the prolonged 14-day treatment and
6-h washout analogous to the described treatment scheme (Figure 2) and (D) an additional 4-day washout. Reported enzyme
activity was normalized to the activity of untreated mutant control cells. For the statistical evaluation, DGJ and BTZ
single treatments were compared with the untreated condition, the combination was compared with DGJ single treatment. (E)
GLAp.R301G/° fibroblasts were treated for 7 days as in (A) and lyso-Gb3 was normalized to the DMSO-treated cells. All results
are normalized to the untreated GLAp.R301Q/° cells. Data are plotted as mean ± SD from 4 (A) or 3 (B–E) independent
experiments. Statistics: Differences between the groups were analyzed using One-way ANOVA with post-hoc Dunnett test
(*, **, ***P-values of 0.05, 0.01 and 0.001); n.s., not significant.
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containing single treatments of BTZ and MG132 and the combination treatment of the latter with DGJ is
located at a considerable distance from the cluster containing the controls, indicating a major impact on tran-
scription. This is in line with our findings on the phenotypic effects of these proteostasis modifiers as shown
above. Finally, a cluster containing CLC and EerI features PC1 scores close to zero; this suggests that the tran-
scriptomic effect of those drugs is smaller than that of MG132 and BTZ. Furthermore, the underlying gene
expression changes are likely to affect distinct sets of genes, implying different modes of action of the drugs.
The treatment with MG132 and BTZ regulated the expression of 1332 and 1060 genes, respectively
(Supplementary Tables S2 and S3). CLC and EerI changed the expression of 471 and 512 genes, respectively.
The intersection of those four sets of differentially expressed genes contained 235 genes. Treatment with DGJ
and ABX caused no substantial change in gene expression, with zero and two differentially expressed genes,
respectively. We identified 86 biological pathways by enrichment analysis using the WikiPathways collection
[49] that show gene content overlap with the 235 consensus genes, and calculated the statistical significance
thereof; Table 2 gives the most significant pathways (P≤ 0.001, hypergeometric test) of which
Hs_Proteasome_Degradation (WP183), Hs_Parkin-Ubiquitin_Proteasomal_System_pathway (WP2359) and
Hs_NRF2_pathway (WP2884) stand out, as these are directly proteostasis-related pathways. Other pathways
such as Hs_Histone_Modifications (WP2369), Hs_Cell_Cycle (WP179) and Hs_Nucleotide_Metabolism
(WP404) may be indicative of involved gene regulatory mechanisms. An effect on various
proteostasis-associated pathways can also be demonstrated using the differentially expressed genes of each indi-
vidual treatment (Supplementary Tables S4–S7).
To obtain a more proteostasis/ERAD focused view, we intersected the list of differentially expressed genes
with our proteostasis genes identified (see Materials and methods). Indeed, of the 357 proteostasis-related
genes, 6 were not annotated on the microarray and, hence, excluded from the analysis, and 64 (18.2%), were
differentially expressed in at least one of the treatments (Figure 7A, Tables 3, Supplementary Tables S8 and S9),
significantly more than expected by chance (P≤ 4.13 × 10−20, hypergeometric test). It is of note that of those
64 differentially expressed genes, 60 were up-regulated, while only 4 were down-regulated, in at least one treat-
ment (Figure 7A). Altogether, 29 signature genes were common to all four treatments (BTZ, MG132, CLC and
Figure 6. PRs show distinct effects on proteasomal activity and GLA gene expression in GLAp.R301Q/° fibroblasts.
(A) Proteasomal activity under the influence of proteostasis regulators. GLAp.R301Q/° fibroblasts were PR-treated for 2 h and
immediately harvested in PBS. The obtained cell suspensions were then used for the luminometric measurement of
chymotrypsin-like proteasomal activity. Results were normalized to the DMSO-treated GLAp.R301Q/° cells. The data are reported
as mean ± SD of five independent experiments. Statistics: One-way ANOVA with post-hoc Dunnett test (*, **, ***P-values of
0.05, 0.01 and 0.001); n.s., not significant. (B) PRs with different effects on GLA expression. Relative GLA mRNA expression
was analyzed by quantitative RT-PCR. Ahead of RT-PCR, GLAp.R301Q/° fibroblasts were treated for 24 h with indicated
concentrations of PRs. The data represent 3–5 independent experiments and are plotted as mean ± SD relative to DMSO
treatment. Statistics: Differences between the groups were analyzed using One-way ANOVA with post-hoc Dunnett test
(*, **, ***P-values of 0.05, 0.01 and 0.001); n.s., not significant.
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EerI). Fifty-seven genes underwent differential expression upon BTZ treatment (Figure 7B). Mapping these
genes on the functional chart of proteostasis suggests their involvement in subcategories like ‘misfolded protein
recognition’ and ‘proteasomal degradation’ (Figure 7C). To investigate whether there were already differences in
baseline gene expression in the GLAp.R301Q/° cells, we compared the gene expression profiles of the FD cells
with the 4 WT cell lines. PCA was applied to all 29 799 (Supplementary Figure S5A) and the 351 proteostasis
related (Supplementary Figure S5B) probesets. The high inter-cluster variance was observed for all five cell lines
indicating that the FD cells were no less different than the WT lines among themselves. A more detailed view
at the proteostasis genes showed no signs of differential regulation or ER stress. Only 19 genes were different
between the GLAp.R301Q/° cells and at least one WT line, but not a single proteostasis gene showed rectified
regulation to all 4 WT lines (Supplementary Figure S5C).
Discussion
The aim of the present study was to identify candidate small molecules able to increase mutant α-Gal A activity
in patient-derived fibroblasts, and to provide a deeper understanding of the mechanisms initiated by the PRs
that may be responsible for the effect on α-Gal A. We have demonstrated the efficacy of the PRs MG132, BTZ,
CLC and EerI as potential drugs for FD by increasing enzyme activity of variant forms of the α-Gal A. We
have further shown synergistic increase in mutant α-Gal A activity by combination of PRs with the clinically
approved drug DGJ (trade name: Galafold [50]). The results of the current study can, therefore, be a valuable
indication for a future clinical combination application of PRs with one of the approved treatments, e.g. the
PC.
Due to a large number of variants leading to marginally stable α-Gal A protein, FD can be referred to as a
protein misfolding disease for this portion of the variants. Misfolding of α-Gal A results in premature proteaso-
mal degradation of the often still catalytically active enzyme [34]. Thus, an insufficient number of enzyme
molecules are transported to the lysosomes, resulting in a diminished degradation of substrates and their accu-
mulation within the cells and the extracellular space [6,51,52]. A first step towards the elimination of cellular
dysfunction in protein misfolding diseases associated with loss-of-function mutations seems to be to increase
the reduced protein amount of the damaged protein or enzyme in the cells. Proteostasis regulating drugs are
interesting options to correct these particular phenotypes. In an approach to identify novel highly effective PRs
and unravel their mode of action, we identified BTZ amongst others as being (i) highly effective and (ii) super-
ior to the FDA-approved PC DGJ in attenuating hallmark pathology (increase in α-Gal A activity and decrease
Table 2 Overrepresented signaling pathways within the intersection of
global transcriptional signatures obtained from MG132, BTZ, CLC and
EerI
No. WIKI pathway
1 Hs_Proteasome_Degradation_WP183
2 Hs_Histone_Modifications_WP2369
3 Hs_Retinoblastoma_(RB)_in_Cancer_WP2446
4 Hs_Parkin-Ubiquitin_Proteasomal_System_pathway_WP2359
5 Hs_Gastric_Cancer_Network_1_WP2361
6 Hs_Pentose_Phosphate_Pathway_WP134
7 Hs_NRF2_pathway_WP2884
8 Hs_Benzo(a)pyrene_metabolism_WP696
9 Hs_Cell_Cycle_WP179
10 Hs_Polyol_Pathway_WP690
11 Hs_Nucleotide_Metabolism_WP404
12 Hs_Oxytocin_signaling_WP2889
Shown are the significantly overrepresented pathways with the 12 lowest corresponding
P-values. bold: proteostasis-associated pathways.
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Figure 7. Proteostasis-associated transcriptional signature of PR-treated GLAp.R301Q/° fibroblasts.
(A) VENN diagram of differentially expressed proteostasis genes after the treatment of GLAp.R301Q/° fibroblasts with PRs. An
intersection of 29 proteostasis genes was differentially expressed in all four treatments. The majority of the proteostasis genes
was up-regulated and only a few were down-regulated. For detail, please refer to Supplementary Tables S8 and S9 (B)
Heatmap of the 57 BTZ-regulated genes. (C) Visualization of the proteostasis gene signature of BTZ on a functional chart of
ERAD/proteostasis. The chart includes 254 of the 357 manually reviewed proteostasis components based on their biological
function in the network. Differentially expressed genes are indicated in red (up-regulation) and green (down-regulation).
Differential gene expression was defined by >1.5-fold difference with a P-value threshold of 0.05.
Table 3 Number of differentially expressed proteostasis genes after the treatment with DGJ and PRs
Genes
Treatment
DGJ MG132 BTZ CLC EerI ABX DGJ +MG132 DGJ + EerI DGJ + ABX
Up-regulated genes 0 58 55 36 35 0 64 41 0
Down-regulated genes 0 4 2 0 3 0 3 2 0
Sum of regulated genes 0 62 57 36 38 0 67 43 0
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in biomarker lyso-Gb3 levels in patient fibroblast) by acting on several involved pathways (increasing gene
expression, decreasing proteasomal activity). Of note, BTZ is an FDA-approved proteasome inhibitor for the
treatment of plasmocytome (trade name: Velcade ® [53]) and is thus available for re-positioning approaches.
In the GLAp.R301Q/° fibroblasts DGJ was able to increase enzyme activity in a concentration-dependent
manner. A 2-fold increase in enzyme activity restored ∼60% of wild-type activity in the GLAp.R301Q/° fibroblasts
cells at a concentration of 200 mM (Supplementary Figure S3A). Nevertheless, a washout phase of 6 h after
treatment had to elapse to unfold the full DGJ effect. The screening of different PRs revealed that MG132, BTZ
and CLC showed the ability to increase the activity of α-Gal A as well, with concentrations of 0.3 mM (for a
2.1-fold increase), 0.005 mM (2.1-fold increase) and 5 mM (1.7-fold increase) for MG132, BTZ and CLC,
respectively (Figure 2A). EerI was able to increase α-Gal A activity in combination with DGJ above the level of
the single DGJ treatment and was, therefore, also regarded as an effective PR. The optimal concentration of
BTZ to increase α-Gal A activity was 5 nM and, therefore, lower than BTZ concentrations used in other studies
on NPC1 and Pompe disease [20,54].
The results for a second cell line, GLAp.R301G/° fibroblasts, could reproduce the efficacy of the individual PRs,
using the most effective concentration established in the first cell line. It is noteworthy that the treatment with the
PRs MG132, BTZ and CLC as a mono-therapy as well as in combination with DGJ showed a trend towards a
stronger responsiveness of the p.R301G variant than observed in the GLAp.R301Q/° cells. EerI also tended to be
effective as a mono-therapy in the GLAp.R301G/° fibroblasts (FC: 1.54 ± 0.14, not significant, Figure 2B) at a con-
centration of 6 mM, while no activity change was observed in GLAp.R301Q/° fibroblasts (FC: 1.09 ± 0.25, not signifi-
cant, Figure 2A). DGJ, on the other hand, demonstrated a comparable efficacy in both fibroblast lines. It is still
too early to conclude about the different responsiveness of the two GLA variants since only one cell line per geno-
type was tested. Although there is not much work on genetic and epigenetic factors as FD phenotype modifiers, it
can be assumed that there are factors independent of the primary GLA gene mutation that have a direct influence
on α-Gal A activity in cell culture and may thus also have an influence on the PR effect. Yet, it is not unlikely
that the p.R301G variant may have a higher effect potential for the PRs used. Since p.R301Q and p.R301G are
known DGJ amenable GLA gene variants [5,55], we can only speculate whether non-amenable variants also
respond positively to the PRs. Due to the observed promising effects on variant enzyme activity and the bio-
marker lyso-Gb3, an extension of the mutation spectrum should be considered in future studies. Even though we
only assessed cells from male hemizygous FD patients, PR treatment is a mutation-specific therapy such as the
PC therapy. Therefore, the tested drugs have the potential for usage in both male and female patients likewise as
is the case with PC therapy, provided the therapy is approved for the respective variant [56].
The approach to administer combinations of a chaperone and a compound with the capability to remodel
cellular proteostasis is relatively new, but it has already been shown to be a promising approach to render
future therapies more efficient [57]. In the present study, it was demonstrated for the first time that the use
of DGJ in combination with the PR BTZ leads to a synergistic increase in variant α-Gal A activity. The
combination of the clinically approved DGJ and BTZ even normalized α-Gal A activity in the patient cells.
The combination of therapeutically used 10 mM DGJ [58] with 5 nM BTZ increased the enzyme activity in
GLAp.R301Q/° fibroblasts up to the normal level (compare Figure 3C). It is worth mentioning that the
maximum plasma concentration of BTZ during standard therapy of patients with multiple myeloma is
∼290 nM [53,59]. The most effective concentration of BTZ for increasing α-Gal A activity in this study was
5 nM. This high potency of BTZ with regard to enzyme activity increase is a good prerequisite for initiating
long-term studies with BTZ. Since FD is a progressive genetic disorder and the therapy has to last a lifetime,
the use of a low concentration formulation will likely reduce adverse effects.
It has already been described that lyso-Gb3 contributes to the pathophysiology of FD [3,60]. A recent study
suggests plasma lyso-Gb3 as an appropriate clinical marker to measure the biochemical response to DGJ since
the levels were found to reflect the disease course in the patients examined [61]. Lyso-Gb3 induces the prolifer-
ation of smooth muscle cells in vitro [3], inhibits cell growth and differentiation of fibroblasts [62] and contri-
butes to the sensitization of peripheral nociceptive neurons [60]. Thus, therapeutic intervention is expected to
reduce lyso-Gb3 in order to improve FD pathology. After a period of 7 days the BTZ treatment lowered
lyso-Gb3 by 32% in GLAp.R301Q/° fibroblasts (Figure 5A), after 14 days, the cells demonstrated a 60% reduction
(Figure 5B). Even though enzyme activity was close to normal (or even completely normalized in the DGJ/BTZ
combination), lyso-Gb3 clearance progressed slowly. After 14 days the level was still markedly above the level
within the wild-type cells. Of note, lyso-Gb3 was only marginally reduced by DGJ even though mono-therapy
was as effective as the BTZ mono-therapy when considering enzyme activity. Since DGJ is a reversible
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competitive inhibitor of α-Gal A and acts as active-site-specific chaperone [63], its efficacy seems to depend
very much on the washout period and not on the on-treatment period, as after 7 (+4)-day and 14 (+4)-day
washout phases no significant difference was found. Another study has demonstrated that Gb3 degradation was
inhibited by the structurally similar lyso-Gb3 in vitro and in vivo, likely due to direct inhibition of α-Gal A [3],
which may jeopardize the usefulness of ERT or another inhibitor of the enzyme such as DGJ for certain
advanced FD patients with very high lyso-Gb3 levels.
In contrast, the obtained reduction using BTZ seems to be linear to the ‘on-treatment’ period, as the doubled
treatment duration led to a further ∼50% reduction in the lyso-Gb3 level. BTZ function could be influenced by
its ability to increase autophagy [64,65] and lysosomal exocytosis [66], which could contribute to the better
clearance effect in an α-Gal A independent manner. This argues for an extension of the range of applications
to patients who carry variants that do not respond sufficiently to DGJ or who do not express any functional
enzyme at all, for example in combination with ERT [67]. Despite therapeutic success in FD patients harboring
the amenable p.N215S α-Gal A variant, in which it was also noted that lyso-Gb3 was reduced under treatment,
chaperone treatment may not be sufficiently effective for all gene variants whose in vitro amenability is proven
[61]. Combination therapy using DGJ/BTZ is highly likely to be a more effective option here.
Mechanistically, we were able to highlight that an important aspect of effective PRs in FD is the ability to
induce GLA gene expression. It has already been shown in a previous study that GLA expression is particularly
highly responsive to MG132 treatment compared with other lysosomal genes in Gaucher patient fibroblasts
[28]. This conclusion can be extended to the effect that all tested proteasomal inhibitors as well as EerI cause a
significant increase in GLA gene expression. However, the ineffective CTR also increased GLA gene expression
significantly. In addition, we addressed the aspect of inhibition of proteasomal activity. It has already been
shown that proteasome inhibitors reduce the degradation of misfolded lysosomal proteins, thus increasing their
transport to the lysosomes [15,16,53]. Our data show that the most effective concentrations of MG132, BTZ
and CLC were able to inhibit the proteasome. There are indications that proteasome inhibition plays a central
role in the observed effects on the α-Gal A, but since there appears to be no correlation between the intensity
of proteasome inhibition and the increase in α-Gal A activity, the need for a concomitant proteasome inhib-
ition on the quality of the α-Gal A enhancing effect needs further investigation.
Several studies describe that the mechanism of action of PRs is, amongst others, based on the regulation of
gene expression of proteostasis genes [15,16,27]. Furthermore, it is known that the proteasomal system crucially
influences gene expression [68]. We took a detailed look at gene expression in GLAp.R301Q/° fibroblasts and
demonstrated that the effective PRs have a strong impact on global and proteostasis-associated gene expression.
The transcriptional signatures of MG132, BTZ, CLC and EerI exhibited regulation of numerous ERAD genes,
most of which were up-regulated. MG132 and BTZ showed similar, only slightly different, patterns regarding
the globally regulated genes. Of the 1332 (MG132) and 1060 (BTZ) regulated genes, 990 were found in both
signatures. Both treatments were statistically indistinguishable (P < 2 × 10−16, hypergeometric test), indicating
the mechanistic identity and equiefficacy at the applied concentrations that were most effective on variant
α-Gal A (0.3 mM MG132; 5 nM BTZ). However, proteasomal inhibition was significantly different at the con-
centrations we used (Figure 6A), which suggests a subordinate role for the strength of the inhibitory effect.
This is also supported by the fact that the application of 50 nM BTZ increased the inhibition of the proteasome
but did not lead to an increased α-Gal A activity (Supplementary Figure S3C). Furthermore, many proteasomal
genes were induced. One reason for this might be based on the transcription factors Nrf1 and Nrf2, whose deg-
radation is reduced under treatment with proteasomal inhibitors [69]. Downstream genes of Nrf2 are related to
oxidative stress [70] and this pathway was identified by our analysis of the signature genes (Table 2). However,
even though EerI slightly elevated proteasomal activity, proteasomal genes were likewise elevated. EerI inhibits
the retrograde transport of proteins from the ER into the cytosol, which are intended for degradation. We
speculate that a feedback pathway between proteasome and nucleus leads to an increase in the expression of
proteasomal subunits, as the proteasomes cannot perceive or degrade substrate material due to this blockade.
Transcriptional signatures also demonstrated the regulation of PERK and ATF6 signaling pathways while the
IRE1 pathway was not affected (Figure 7C). The latter is mainly associated with ERAD while PERK and ATF6
are associated with increased folding capacities in the ER [71]. Various ER-associated chaperones were
up-regulated as well, indicating an increased cellular protein folding capacity. Therefore, the effect on transcrip-
tional regulation may be beneficial to enhance variant α-Gal A. We assume that among the differentially regu-
lated proteostasis components, some could potentially be suitable for more specific pharmacological targeting.
Although the potential to identify new treatment targets these pronounced gene expression signatures, such
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phenotypes may raise the question of therapeutic versus adverse effects. This aspect should not be ignored
when using proteasomal inhibitors as drug candidates. DGJ, on the other hand, appears to be in this aspect an
extraordinarily neutral drug.
Low molecular mass compounds such as PC and PRs have proven to be promising approaches to overcom-
ing protein folding diseases in recent years. In our study, the mechanisms of action complement each other in
such a way that the synergy of the active substances can be accomplished. While DGJ increases the processing
and transport of variant α-Gal A and therefore reduces its degradation [63], the studied PRs apparently
mediate their effect via effective proteasomal degradation inhibition and a pronounced effect on cellular gene
regulation (Figure 8). The positive-inducing effect on the GLA gene itself, which provides an increased amount
of α-Gal A in the ER for folding and processing indicates the strong association between proteasomal and lyso-
somal systems. Indeed, 33 (7.6%, P≤ 0.006, hypergeometric test) of the 432 annotated signature genes [72]
were differentially expressed in any of the PRs treatments including genes deficient in other LSD
(Supplementary Figure S6, Supplementary Table S10). In sum, the PRs had a vast effect on the cellular gene
expression regulation of degradational pathways, more specifically on the proteostasis network, which is likely
to support the action of the drugs.
Figure 8. Model of the DGJ and BTZ mechanism leading to synergy in the recovery of α-Gal A function.
α-Gal A level is determined by mRNA transcription and efficiency of synthesis and protein folding. In the state of falsely
incorporated amino acids due to point mutations, there is a shift in the balance between folding and misfolding of the protein.
The pharmacological chaperone DGJ binds to the active site of the enzyme causing the enzyme to fold into a
thermodynamically more stable state and α-Gal A is then less efficiently retained by the ER quality control. BTZ inhibits
proteasomal activity and may, therefore, make a higher amount of α-Gal A available for DGJ. An equally important aspect of
the BTZ effect seems to be its influence on the induction of the GLA gene expression and, speculatively, also the influence on
the expression of many other genes putatively involved in proteostasis. As a result, more α-Gal A leaves the ER and is
transported to the lysosomes.
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It can be assumed that a positive effect can only be achieved if the properties of the PRs are combined in a
proportion that does justice to the respective misfolded protein variant. In FD, the proteasomal inhibitors
studied here seem to best fulfill this need and are therefore candidates for clinical application.
In conclusion, we identified PRs that effectively elevate mutant α-Gal A activity and reduce lyso-Gb3 in the
cells. The mechanism of action of the effective PRs included marked inhibition of the proteasome and a pro-
nounced elevation of GLA gene expression as two main effectors on α-Gal A enzyme activity. Additionally, we
analyzed the transcriptional effects of the PRs and identified a panel of commonly regulated proteostasis genes.
We suggest that these transcriptional effects describe important aspects that influence the efficacy of PRs.
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